Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lymphoma

Known as: Lymphoma (Hodgkin's and Non-Hodgkin's), Reticulolymphosarcomas, Lymphomatous 
Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the… Expand
National Institutes of Health

Related topics

Related topics

46 relations
ATM protein, humanAtypical lymphocyteB-Cell LymphomasBUB1 gene
Expand

Narrower (7)

Immunoblastic Large-Cell LymphomaLymph Node NeoplasmLymphocytic NeoplasmLymphosarcoma Involving Spleen
Expand

Broader (2)

Lymphoid organ structureNeoplasms

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Chimeric Antigen Receptor Therapy.
Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
Review
2018
Review
2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205…
Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 2
Is this relevant?
Review
2018
Review
2018
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response… Expand
  • figure 1
Is this relevant?
Review
2018
Review
2018
CAR T cell immunotherapy for human cancer
Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor… Expand
Is this relevant?
Review
2018
Review
2018
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
Background This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2018
Review
2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK… Expand
Is this relevant?
Review
2018
Review
2018
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Purpose Approximately 1% to 2% of non-small-cell lung cancers (NSCLCs) harbor a c-ros oncogene 1 ( ROS1) rearrangement… Expand
Is this relevant?
Review
2017
Review
2017
New insights into the role of EMT in tumor immune escape
Novel immunotherapy approaches have provided durable remission in a significant number of cancer patients with cancers previously… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2017
Review
2017
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
PD-1-PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. However, studies… Expand
Is this relevant?
Review
2017
Review
2017
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
Natural killer (NK) cells are innate immune cells that show strong cytolytic function against physiologically stressed cells such… Expand
  • table 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE